COVID-19-associated mucormycosis and treatments

Vetriselvan Subramaniyan; Shivkanya Fuloria; Hari Kumar Darnal; Dhanalekshmi Unnikrishnan Meenakshi; Mahendran Sekar; Rusli Bin Nordin; Srikumar Chakravarthi; Kathiresan V. Sathasivam; Shah Alam Khan; Yuan Seng Wu; Usha Kumari; Kalvatala Sudhakar; Rishabha Malviya; Vipin Kumar Sharma; Neeraj Kumar Fuloria

doi:10.4103/1995-7645.326253

COVID-19-associated mucormycosis and treatments

Vetriselvan Subramaniyan
, Shivkanya Fuloria
, Hari Kumar Darnal
, Dhanalekshmi Unnikrishnan Meenakshi
, Mahendran Sekar
, Rusli Bin Nordin
, Srikumar Chakravarthi
, Kathiresan V. Sathasivam
, Shah Alam Khan
, Yuan Seng Wu
, Usha Kumari
, Kalvatala Sudhakar
, Rishabha Malviya
, Vipin Kumar Sharma
, Neeraj Kumar Fuloria

Malaysia Jeffrey Cheah Sch of Med & HS

Research output: Contribution to journal › Review Article › Other › peer-review

13 Citations (Scopus)

Abstract

In the current pandemic, COVID-19 patients with predisposing factors are at an increased risk of mucormycosis, an uncommon angioinvasive infection that is caused by fungi with Mucor genus which is mainly found in plants and soil. Mucormycosis development in COVID-19 patient is related to various factors, such as diabetes, immunocompromise and neutropenia. Excessive use of glucocorticoids for the treatment of critically ill COVID-19 patients also leads to opportunistic infections, such as pulmonary aspergillosis. COVID-19 patients with mucormycosis have a very high mortality rate. This review describes the pathogenesis and various treatment approaches for mucormycosis in COVID-19 patients, including medicinal plants, conventional therapies, adjunct and combination therapies.

Original language	English
Pages (from-to)	401-409
Number of pages	9
Journal	Asian Pacific Journal of Tropical Medicine
Volume	14
Issue number	9
DOIs	https://doi.org/10.4103/1995-7645.326253
Publication status	Published - 1 Sept 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

COVID-19
Immunosuppression
Mucormycosis
Pathogenesis
Treatment

Access to Document

10.4103/1995-7645.326253Licence: CC BY

Cite this

Subramaniyan, V., Fuloria, S., Darnal, H. K., Meenakshi, D. U., Sekar, M., Nordin, R. B., Chakravarthi, S., Sathasivam, K. V., Khan, S. A., Wu, Y. S., Kumari, U., Sudhakar, K., Malviya, R., Sharma, V. K., & Fuloria, N. K. (2021). COVID-19-associated mucormycosis and treatments. Asian Pacific Journal of Tropical Medicine, 14(9), 401-409. https://doi.org/10.4103/1995-7645.326253

@article{727d40a04c7448db8909307baaf5d5fb,

title = "COVID-19-associated mucormycosis and treatments",

abstract = "In the current pandemic, COVID-19 patients with predisposing factors are at an increased risk of mucormycosis, an uncommon angioinvasive infection that is caused by fungi with Mucor genus which is mainly found in plants and soil. Mucormycosis development in COVID-19 patient is related to various factors, such as diabetes, immunocompromise and neutropenia. Excessive use of glucocorticoids for the treatment of critically ill COVID-19 patients also leads to opportunistic infections, such as pulmonary aspergillosis. COVID-19 patients with mucormycosis have a very high mortality rate. This review describes the pathogenesis and various treatment approaches for mucormycosis in COVID-19 patients, including medicinal plants, conventional therapies, adjunct and combination therapies.",

keywords = "COVID-19, Immunosuppression, Mucormycosis, Pathogenesis, Treatment",

author = "Vetriselvan Subramaniyan and Shivkanya Fuloria and Darnal, \{Hari Kumar\} and Meenakshi, \{Dhanalekshmi Unnikrishnan\} and Mahendran Sekar and Nordin, \{Rusli Bin\} and Srikumar Chakravarthi and Sathasivam, \{Kathiresan V.\} and Khan, \{Shah Alam\} and Wu, \{Yuan Seng\} and Usha Kumari and Kalvatala Sudhakar and Rishabha Malviya and Sharma, \{Vipin Kumar\} and Fuloria, \{Neeraj Kumar\}",

year = "2021",

month = sep,

day = "1",

doi = "10.4103/1995-7645.326253",

language = "English",

volume = "14",

pages = "401--409",

journal = "Asian Pacific Journal of Tropical Medicine",

issn = "1995-7645",

publisher = "Medknow Publications",

number = "9",

}

TY - JOUR

T1 - COVID-19-associated mucormycosis and treatments

AU - Subramaniyan, Vetriselvan

AU - Fuloria, Shivkanya

AU - Darnal, Hari Kumar

AU - Meenakshi, Dhanalekshmi Unnikrishnan

AU - Sekar, Mahendran

AU - Nordin, Rusli Bin

AU - Chakravarthi, Srikumar

AU - Sathasivam, Kathiresan V.

AU - Khan, Shah Alam

AU - Wu, Yuan Seng

AU - Kumari, Usha

AU - Sudhakar, Kalvatala

AU - Malviya, Rishabha

AU - Sharma, Vipin Kumar

AU - Fuloria, Neeraj Kumar

PY - 2021/9/1

Y1 - 2021/9/1

N2 - In the current pandemic, COVID-19 patients with predisposing factors are at an increased risk of mucormycosis, an uncommon angioinvasive infection that is caused by fungi with Mucor genus which is mainly found in plants and soil. Mucormycosis development in COVID-19 patient is related to various factors, such as diabetes, immunocompromise and neutropenia. Excessive use of glucocorticoids for the treatment of critically ill COVID-19 patients also leads to opportunistic infections, such as pulmonary aspergillosis. COVID-19 patients with mucormycosis have a very high mortality rate. This review describes the pathogenesis and various treatment approaches for mucormycosis in COVID-19 patients, including medicinal plants, conventional therapies, adjunct and combination therapies.

AB - In the current pandemic, COVID-19 patients with predisposing factors are at an increased risk of mucormycosis, an uncommon angioinvasive infection that is caused by fungi with Mucor genus which is mainly found in plants and soil. Mucormycosis development in COVID-19 patient is related to various factors, such as diabetes, immunocompromise and neutropenia. Excessive use of glucocorticoids for the treatment of critically ill COVID-19 patients also leads to opportunistic infections, such as pulmonary aspergillosis. COVID-19 patients with mucormycosis have a very high mortality rate. This review describes the pathogenesis and various treatment approaches for mucormycosis in COVID-19 patients, including medicinal plants, conventional therapies, adjunct and combination therapies.

KW - COVID-19

KW - Immunosuppression

KW - Mucormycosis

KW - Pathogenesis

KW - Treatment

UR - https://www.scopus.com/pages/publications/85116601819

U2 - 10.4103/1995-7645.326253

DO - 10.4103/1995-7645.326253

M3 - Review Article

AN - SCOPUS:85116601819

SN - 1995-7645

VL - 14

SP - 401

EP - 409

JO - Asian Pacific Journal of Tropical Medicine

JF - Asian Pacific Journal of Tropical Medicine

IS - 9

ER -

COVID-19-associated mucormycosis and treatments

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Cite this